CORCEPT THERAPEUTICS INC Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
CORCEPT THERAPEUTICS INC (CORT) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 2.30 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-02-24
- CORCEPT THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2016-03-31 was 18.84M shares, a 7.25% increase year-over-year.
- CORCEPT THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2015-03-31 was 17.57M shares, a 24.45% decline year-over-year.
- CORCEPT THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2014-03-31 was 23.25M shares, a 0.89% increase year-over-year.
- CORCEPT THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2013-03-31 was 23.05M shares, a 19.01% increase year-over-year.
- CORCEPT THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 2.30M shares, a 14.81% decline from fiscal 2024.
- CORCEPT THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 2.70M shares, a 70.33% decline from fiscal 2023.
- CORCEPT THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 9.10M shares, a 24.66% increase from fiscal 2022.
- CORCEPT THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 7.30M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2025-12-31 | 2.30M shares 10-K · filed 2026-02-24 | |||
| 2024-12-31 | 2.70M shares 10-K · filed 2026-02-24 | |||
| 2023-12-31 | 9.10M shares 10-K · filed 2026-02-24 | |||
| 2022-12-31 | 7.30M shares 10-K · filed 2023-02-28 | |||
| 2016-12-31 | 17.66M shares 10-K · filed 2017-03-06 | |||
| 2016-03-31 | 18.84M shares 10-Q · filed 2016-05-04 | |||
| 2015-12-31 | 16.20M shares 10-K · filed 2017-03-06 | |||
| 2015-09-30 | 17.03M shares 10-Q · filed 2015-11-06 | |||
| 2015-06-30 | 17.43M shares 10-Q · filed 2015-08-07 | |||
| 2015-03-31 | 17.57M shares 10-Q · filed 2016-05-04 | |||
| 2014-12-31 | 22.75M shares 10-K · filed 2017-03-06 | |||
| 2014-09-30 | 22.93M shares 10-Q · filed 2015-11-06 | |||
| 2014-06-30 | 22.66M shares 10-Q · filed 2015-08-07 | |||
| 2014-03-31 | 23.25M shares 10-Q · filed 2015-05-08 | |||
| 2013-12-31 | 23.29M shares 10-K · filed 2016-03-10 | |||
| 2013-09-30 | 23.20M shares 10-Q · filed 2014-11-07 | |||
| 2013-06-30 | 23.40M shares 10-Q · filed 2014-08-08 | |||
| 2013-03-31 | 23.05M shares 10-Q · filed 2014-05-12 | |||
| 2012-12-31 | 20.53M shares 10-K · filed 2015-03-13 | |||
| 2012-09-30 | 19.92M shares 10-Q · filed 2013-11-12 | |||
| 2012-06-30 | 19.73M shares 10-Q · filed 2013-08-09 | |||
| 2012-03-31 | 19.36M shares 10-Q · filed 2013-05-08 | |||
| 2011-12-31 | 19.43M shares 10-K · filed 2014-03-14 | |||
| 2011-09-30 | 19.68M shares 10-Q · filed 2012-11-08 | |||
| 2011-06-30 | 19.07M shares 10-Q · filed 2012-08-09 | |||
| 2010-12-31 | 17.16M shares 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |